Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

NCT05389267 is registered in ClinicalTrials.gov with Laboratoires Thea as lead sponsor.

NCT NCT05389267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05389267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
Lead sponsor
Laboratoires Thea
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 5, 2022
Completion date
December 31, 2024
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, ocular hypertension